Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 5Glioma 5Glioblastoma 5Neoplasm Metastasis 3Uterine Cervical Dysplasia 2Keratosis, Actinic 2Ependymoma 2Breast Neoplasms 2Brain Neoplasms 2Astrocytoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sialorrhea 1Sarcoma 1Precancerous Conditions 1Non-Muscle Invasive Bladder Neoplasms 1Neurofibromatosis 1 1Medulloblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1Bone Neoplasms 1Atypical Squamous Cells of the Cervix 1Adenocarcinoma 1

Interventions

vocimagene amiretrorepvec 1enfortumab vedotin 1catumaxomab 1apatorsen 1Ty21a typhoid vaccine 1Therapeutics 1Photochemotherapy 1Paclitaxel 1Mitomycin 1Imiquimod 1Gemcitabine 1Flucytosine 1Ethacrynic Acid 1Bevacizumab 1BCG Vaccine 1Antibodies 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Non-Muscle Invasive Bladder Neoplasms × Imiquimod × Clear all
NCT05375903 2026-01-14

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

UroGen Pharma Ltd.

Phase 1 Completed
51 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡